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COVID-19: LATE STAGE VACCINE CANDIDATES
Unwarranted optimism about vaccine efficacy
David Skegg, 1 Neil Pearce2
Interim results from phase III trials of the vaccine developed by the University of Oxford and AstraZeneca
were announced through press releases on 23 November. Much has been made of an apparent difference in
efficacy between the intended regimen (two full doses of the vaccine) and another regimen (a half dose
followed by a full dose). Whereas the efficacy in people given the planned combination was found to be 62%,
that in the second group was 90%. Immunologists have suggested possible mechanisms to explain why
startingwith a reduceddosemight bemore effective.1 Their theories have fuelledhopes that 90%effectiveness
could be achieved in vaccination programmes.
There has been far too little acknowledgment that chance is a likely explanation for the different results
between the twogroups. In clinical studies, subgroupanalysesmust alwaysbe treatedwith caution—especially
when there was no prior hypothesis that an intervention would be more effective in one subgroup. About a
quarter of the vaccinated participants received an initial lower dose of vaccine because of an error in
preparation, not because anyone suggested that this regimen would be superior. From the numbers released,
it is clear that the difference in results between the two groups could have occurred by chance (and would
be marginal in terms of conventional criteria for statistical significance). It is also concerning that the two
groups appeared to have different age distributions, as well as different distributions across participating
countries.
The notion that a serendipitous error might have led to the discovery of a more effective regimen is appealing.
Unless there is further evidence from clinical trials, however, it would be wise to assume that the only reliable
estimate of efficacy comes from the full dataset—that is, 70%.
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